Evidence map›Paper›PMID 35275994›Full record

ArticleDiabetes care2022

Admission Blood Glucose Level and Its Association With Cardiovascular and Renal Complications in Patients Hospitalized With COVID-19.

Tom Norris, Cameron Razieh, Thomas Yates, Francesco Zaccardi, Clare L Gillies, Yogini V Chudasama, Alex Rowlands, Melanie J Davies, Gerry P McCann, Amitava Banerjee and 6 more

Open access · greenAbstract readMulticenter Study
In one paragraph

Article in Diabetes care, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Recombinant tissue plasminogen activator (rTPA) management for first onset acute ischemic stroke with covid -19 and non-covid -19 patients.Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 1 country.

Tom NorrisDiabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, U.K.ORCID 0000-0002-9140-0776
Cameron RaziehDiabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, U.K.
Thomas YatesDiabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, U.K.
Francesco ZaccardiDiabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, U.K.
Clare L GilliesDiabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, U.K.
Yogini V ChudasamaLeicester Real World Evidence Unit, Diabetes Research Centre, University of Leicester, Leicester, U.K.ORCID 0000-0002-6777-0064
Alex RowlandsDiabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, U.K.
Melanie J DaviesDiabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, U.K.
Gerry P McCannNational Institute for Health Research Leicester Biomedical Research Centre, Leicester General Hospital, Leicester, U.K.
Amitava BanerjeeInstitute of Health Informatics, University College London, London, U.K.
Annemarie B DochertyCentre for Medical Informatics, Usher Institute, University of Edinburgh, Edinburgh, U.K.
Peter J M OpenshawNational Heart and Lung Institute, Imperial College London, London, U.K.
J Kenneth BaillieRoslin Institute, University of Edinburgh, Edinburgh, U.K.
Malcolm G SempleNational Institute for Health Research Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, U.K.
Claire A LawsonDiabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, U.K.
Kamlesh KhuntiDiabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, U.K.ORCID 0000-0003-2343-7099
University of Leicester · GBEdinburgh Royal Infirmary · GBImperial College London · GBRoslin Institute · GBUniversity College London · GBUniversity of Liverpool · GB

Funding

Department of Health CO-CIN-01Medical Research Council MC_PC_19025Medical Research Council MC_PC_19059Medical Research Council MR/V020536/1
6 · The paper itself

Abstract

objectiveTo investigate the association between admission blood glucose levels and risk of in-hospital cardiovascular and renal complications. RESEARCH DESIGN AND

methodsIn this multicenter prospective study of 36,269 adults hospitalized with COVID-19 between 6 February 2020 and 16 March 2021 (N = 143,266), logistic regression models were used to explore associations between admission glucose level (mmol/L and mg/dL) and odds of in-hospital complications, including heart failure, arrhythmia, cardiac ischemia, cardiac arrest, coagulation complications, stroke, and renal injury. Nonlinearity was investigated using restricted cubic splines. Interaction models explored whether associations between glucose levels and complications were modified by clinically relevant factors.

resultsCardiovascular and renal complications occurred in 10,421 (28.7%) patients; median admission glucose level was 6.7 mmol/L (interquartile range 5.8-8.7) (120.6 mg/dL [104.4-156.6]). While accounting for confounders, for all complications except cardiac ischemia and stroke, there was a nonlinear association between glucose and cardiovascular and renal complications. For example, odds of heart failure, arrhythmia, coagulation complications, and renal injury decreased to a nadir at 6.4 mmol/L (115 mg/dL), 4.9 mmol/L (88.2 mg/dL), 4.7 mmol/L (84.6 mg/dL), and 5.8 mmol/L (104.4 mg/dL), respectively, and increased thereafter until 26.0 mmol/L (468 mg/dL), 50.0 mmol/L (900 mg/dL), 8.5 mmol/L (153 mg/dL), and 32.4 mmol/L (583.2 mg/dL). Compared with 5 mmol/L (90 mg/dL), odds ratios at these glucose levels were 1.28 (95% CI 0.96, 1.69) for heart failure, 2.23 (1.03, 4.81) for arrhythmia, 1.59 (1.36, 1.86) for coagulation complications, and 2.42 (2.01, 2.92) for renal injury. For most complications, a modifying effect of age was observed, with higher odds of complications at higher glucose levels for patients age <69 years. Preexisting diabetes status had a similar modifying effect on odds of complications, but evidence was strongest for renal injury, cardiac ischemia, and any cardiovascular/renal complication.

conclusionsIncreased odds of cardiovascular or renal complications were observed for admission glucose levels indicative of both hypo- and hyperglycemia. Admission glucose could be used as a marker for risk stratification of high-risk patients. Further research should evaluate interventions to optimize admission glucose on improving COVID-19 outcomes.

Indexed as

COVID-19Heart FailureStrokeAdultAgedBlood GlucoseHumansIschemiaKidneyProspective StudiesBlood Glucose

Identifiers

PMID35275994
PMCPMC9174963
OpenAlexW4220779246

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.